1-propanol has been researched along with Hyperlipidemias in 16 studies
1-Propanol: A colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical intermediate.
propan-1-ol : The parent member of the class of propan-1-ols that is propane in which a hydrogen of one of the methyl groups is replaced by a hydroxy group.
Hyperlipidemias: Conditions with excess LIPIDS in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pravastatin treatment induced a significant decrease in the TC, LDL-c, and ApoB levels in patients expressing the ApoA1 AA+GA genotype (P < 0." | 2.82 | Relationship between the G75A polymorphism in the apolipoprotein A1 (ApoA1) gene and the lipid regulatory effects of pravastatin in patients with hyperlipidemia. ( He, F; Li, HW; Li, SX; Liu, TN; Wu, CT; Wu, M; Yu, HY; Yuan, W, 2016) |
| "To evaluate the effects and safety of policosanol combined with simvastatin on serum lipids and sex hormones in male patients with hyperlipidemia." | 2.78 | [Effects of policosanol combined with simvastatin on serum lipids and sex hormones in male patients with hyperlipidemia]. ( Gong, X; Tang, M; Wu, SZ, 2013) |
| " Consistent with recent clinical trial data, MP demonstrated an excellent safety profile but produced no significant effects on major lipoproteins when used as monotherapy or when given with concomitant statin therapy." | 2.76 | Modified-policosanol does not reduce plasma lipoproteins in hyperlipidemic patients when used alone or in combination with statin therapy. ( Backes, JM; Gibson, CA; Moriarty, PM; Ruisinger, JF, 2011) |
| " However, its bioavailability is low." | 1.56 | Nanoemulsification of Rice Bran Wax Policosanol Enhances Its Cardio-protective Effects via Modulation of Hepatic Peroxisome Proliferator-activated Receptor gamma in Hyperlipidemic Rats. ( Imam, MU; Ishaka, A; Ismail, M, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Zhai, Z | 1 |
| Liu, J | 1 |
| Niu, KM | 1 |
| Lin, C | 1 |
| Tu, Y | 1 |
| Liu, Y | 1 |
| Cai, L | 1 |
| Liu, H | 1 |
| Ouyang, K | 1 |
| Ishaka, A | 1 |
| Imam, MU | 1 |
| Ismail, M | 1 |
| Tang, M | 1 |
| Wu, SZ | 1 |
| Gong, X | 1 |
| Lee, EY | 1 |
| Yoo, JA | 1 |
| Lim, SM | 1 |
| Cho, KH | 1 |
| Liu, TN | 1 |
| Wu, CT | 1 |
| He, F | 1 |
| Yuan, W | 1 |
| Li, SX | 1 |
| Li, HW | 1 |
| Yu, HY | 1 |
| Wu, M | 1 |
| Elseweidy, MM | 1 |
| Zein, N | 1 |
| Aldhamy, SE | 1 |
| Elsawy, MM | 1 |
| Saeid, SA | 1 |
| Musto, D | 1 |
| Martorelli, L | 1 |
| Russo, M | 1 |
| Esposito, G | 1 |
| Amato, MR | 1 |
| Esposito, P | 1 |
| Riegler, G | 1 |
| Backes, JM | 1 |
| Gibson, CA | 1 |
| Ruisinger, JF | 1 |
| Moriarty, PM | 1 |
| Liu, S | 1 |
| Tan, MY | 1 |
| Zhao, SP | 1 |
| Rong, H | 1 |
| Arruzazabala, ML | 1 |
| Molina, V | 1 |
| Mas, R | 2 |
| Fernández, L | 1 |
| Carbajal, D | 1 |
| Valdés, S | 1 |
| Castaño, G | 2 |
| Menéndez, R | 1 |
| Amor, A | 1 |
| Fernández, JL | 1 |
| González, RL | 1 |
| Lezcay, M | 1 |
| Alvarez, E | 1 |
| Chen, JT | 1 |
| Wesley, R | 1 |
| Shamburek, RD | 1 |
| Pucino, F | 1 |
| Csako, G | 1 |
| Berthold, HK | 1 |
| Unverdorben, S | 1 |
| Degenhardt, R | 1 |
| Bulitta, M | 1 |
| Gouni-Berthold, I | 1 |
| Batista, J | 1 |
| Stüsser, R | 1 |
| Saéz, F | 1 |
| Pérez, B | 1 |
| Sarkar, S | 1 |
| Sonkar, R | 1 |
| Bhatia, G | 1 |
| Tadigoppula, N | 1 |
| Yamada, N | 1 |
| Havel, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Placebo-Controlled, Randomised, Double-Blind, Multi-Centre Clinical Trial on Dose-Dependent Cholesterol-Lowering Effects of Policosanol in Patients With Hypercholesterolaemia With 10 to 80 Mg Policosanol for 12 Weeks[NCT00288483] | Phase 3 | 0 participants | Interventional | 2000-09-30 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for 1-propanol and Hyperlipidemias
| Article | Year |
|---|---|
Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol.
Topics: Anticholesteremic Agents; Coronary Disease; Fatty Alcohols; Humans; Hyperlipidemias; Phytosterols; R | 2005 |
8 trials available for 1-propanol and Hyperlipidemias
| Article | Year |
|---|---|
[Effects of policosanol combined with simvastatin on serum lipids and sex hormones in male patients with hyperlipidemia].
Topics: Adult; Aged; Drug Therapy, Combination; Fatty Alcohols; Gonadal Steroid Hormones; Humans; Hyperlipid | 2013 |
Relationship between the G75A polymorphism in the apolipoprotein A1 (ApoA1) gene and the lipid regulatory effects of pravastatin in patients with hyperlipidemia.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Fatty Alcohols; Humans; Hyperlipidemias; Lipoproteins; | 2016 |
Modified-policosanol does not reduce plasma lipoproteins in hyperlipidemic patients when used alone or in combination with statin therapy.
Topics: Adult; Aged; Amino Acids; Anticholesteremic Agents; Cholesterol, LDL; Drug Therapy, Combination; Fat | 2011 |
[Effects of policosanol on serum lipids and heme oxygenase-1 in patients with hyperlipidemia].
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Fatty Alcohols; Female; Heme Oxygenase-1; Humans | 2012 |
Antiplatelet effects of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Fatty Alcohols; Female; Humans; | 2002 |
Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
Topics: Aged; Anticholesteremic Agents; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Alcohols; Fema | 2002 |
Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.
Topics: Adult; Aged; Anticholesteremic Agents; Double-Blind Method; Fatty Alcohols; Female; Humans; Hypercho | 2006 |
Effect of policosanol on hyperlipidemia and coronary heart disease in middle-aged patients. A 14-month pilot study.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Double-Blind Method; Fatty Alcohols; Female | 1996 |
7 other studies available for 1-propanol and Hyperlipidemias
| Article | Year |
|---|---|
Integrated Metagenomics and Metabolomics to Reveal the Effects of Policosanol on Modulating the Gut Microbiota and Lipid Metabolism in Hyperlipidemic C57BL/6 Mice.
Topics: Animals; Diet, High-Fat; Fatty Alcohols; Gastrointestinal Microbiome; Hyperlipidemias; Lipid Metabol | 2021 |
Nanoemulsification of Rice Bran Wax Policosanol Enhances Its Cardio-protective Effects via Modulation of Hepatic Peroxisome Proliferator-activated Receptor gamma in Hyperlipidemic Rats.
Topics: Animals; Cardiotonic Agents; Diet, High-Fat; Fatty Alcohols; Gene Expression; Homocysteine; Hyperlip | 2020 |
Anti-Aging and Tissue Regeneration Ability of Policosanol Along with Lipid-Lowering Effect in Hyperlipidemic Zebrafish via Enhancement of High-Density Lipoprotein Functionality.
Topics: Aging; Animals; Antioxidants; Brain; Cholesterol Ester Transfer Proteins; Cytoprotection; Fatty Alco | 2016 |
Policosanol as a new inhibitor candidate for vascular calcification in diabetic hyperlipidemic rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Calcification, Physiologic; Dia | 2016 |
[Non-alcoholic hepatic steatosis: the role of policosanols in associated hyperlipidemia].
Topics: Aged; Anticholesteremic Agents; Biomarkers; Body Mass Index; Cholesterol; Cholesterol, LDL; Fatty Al | 2010 |
Synthesis of new N-acryl-1-amino-2-phenylethanol and N-acyl-1-amino-3-aryloxypropanols and evaluation of their antihyperlipidemic, LDL-oxidation and antioxidant activity.
Topics: 1-Propanol; Aegle; Animals; Antioxidants; Chemistry Techniques, Synthetic; Dose-Response Relationshi | 2014 |
Measurement of apolipoprotein B radioactivity in whole blood plasma by precipitation with isopropanol.
Topics: 1-Propanol; Animals; Apolipoproteins B; Chemical Precipitation; Hyperlipidemias; Iodine Radioisotope | 1986 |